Search Results - "Zejnullahu, K"

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor by Ercan, D, Zejnullahu, K, Yonesaka, K, Xiao, Y, Capelletti, M, Rogers, A, Lifshits, E, Brown, A, Lee, C, Christensen, J G, Kwiatkowski, D J, Engelman, J A, Jänne, P A

“…Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib are effective therapies against mutant non-small cell lung cancers…”
Get full text

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer by Engelman, Jeffrey A, Mukohara, Toru, Zejnullahu, Kreshnik, Lifshits, Eugene, Borrás, Ana M, Gale, Christopher-Michael, Naumov, George N, Yeap, Beow Y, Jarrell, Emily, Sun, Jason, Tracy, Sean, Zhao, Xiaojun, Heymach, John V, Johnson, Bruce E, Cantley, Lewis C, Jänne, Pasi A

“…EGFR is frequently mutated and amplified in lung adenocarcinomas sensitive to EGFR inhibitors gefitinib and erlotinib. A secondary mutation, T790M, has been…”
Get full text

OP 85 Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab by Yonesaka, K, Zejnullahu, K, Okamoto, I, Satoh, T, Cappuzzo, F, Souglakos, J, Engelman, J, Varella-Garcia, M, Nakagawa, K, Jänne, P

Get full text

Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway by Cortot, A.B., Repellin, C.E., Shimamura, T., Capelletti, M., Zejnullahu, K., Ercan, D., Christensen, J. G., Wong, K.-K., Gray, N. S., Jänne, P.A.

“…The clinical efficacy of EGFR kinase inhibitors gefitinib and erlotinib is limited by the development of drug resistance. The most common mechanism of drug…”
Get full text